H.C. Wainwright Boosts Price Target for Nektar Therapeutics (NASDAQ: NKTR) Amid Clinical Trial Success
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameNektar Therapeutics
-
Registration countryUSA
-
IndustryPharmaceutical Preparation and Biotechnology
-
М/S&P/F
*** /*** /***









